IL-1 TARGET LICENSE AGREEMENTIl-1 Target License Agreement • November 3rd, 2022 • XOMA Corp • Pharmaceutical preparations • New York
Contract Type FiledNovember 3rd, 2022 Company Industry JurisdictionThis IL-1 TARGET LICENSE AGREEMENT (the “Agreement”) is entered into as of the 24th day of August, 2017 (the “Effective Date”) by and between XOMA (US) LLC, a limited liability company organized under the laws of Delaware having offices at 2910 Seventh St., Berkeley, CA, USA, 94710 (“XOMA”), and Novartis Pharma AG, company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland and registered in the Commercial Register of the Canton of Basel-Stadt, Switzerland, under number CHE-106.052.527 whose registered office is at Lichtstrasse 35, CH 4056 Basel, Switzerland (“Novartis”). XOMA and Novartis are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
Amendment and Restatement to AgreementsAsset Purchase Agreement and License Agreement • November 3rd, 2022 • XOMA Corp • Pharmaceutical preparations
Contract Type FiledNovember 3rd, 2022 Company IndustryThis Amendment and Restatement (“Amendment”) to both the Asset Purchase Agreement (“APA”) and Nanotherapeutics License Agreement (“License Agreement”) is dated February 2, 2017, between XOMA Corporation (“XOMA”) and Nanotherapeutics, Inc. (“Nano”). Capitalized terms not otherwise defined in this Amendment shall have the meaning set forth in the APA and License Agreement.
NANOTHERAPEUTICS LICENSE AGREEMENT, BY AND BETWEEN XOMA (US) LLC and NANOTHERAPEUTICS, INC. March 23, 2016Nanotherapeutics License Agreement • November 3rd, 2022 • XOMA Corp • Pharmaceutical preparations • California
Contract Type FiledNovember 3rd, 2022 Company Industry JurisdictionThis NANOTHERAPEUTICS LICENSE AGREEMENT (this “Agreement”) is entered into as of March 23, 2016 (the “Effective Date”) by and between XOMA (US) LLC, a Delaware limited liability company (“Licensor), and Nanotherapeutics, Inc., a Delaware Corporation (“Licensee”). Each of Licensor and Licensee is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENTLicense Agreement • November 3rd, 2022 • XOMA Corp • Pharmaceutical preparations • New York
Contract Type FiledNovember 3rd, 2022 Company Industry JurisdictionThis LICENSE AGREEMENT (the “Agreement”) is entered into as of the 24th day of August, 2017 (the “Effective Date”) by and between XOMA (US) LLC, a limited liability company organized under the laws of Delaware having offices at 2910 Seventh St., Berkeley, CA, USA, 94710 (“XOMA”), and Novartis Pharma AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland and registered in the Commercial Register of the Canton of Basel-Stadt, Switzerland, under number CHE-106.052.527 whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland (“Novartis”). XOMA and Novartis are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”